Fulgent Genetics, Inc. (FLGT)
FLGT Stock Price Chart
Explore Fulgent Genetics, Inc. interactive price chart. Choose custom timeframes to analyze FLGT price movements and trends.
FLGT Company Profile
Discover essential business fundamentals and corporate details for Fulgent Genetics, Inc. (FLGT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
29 Sept 2016
Employees
1.31k
Website
https://www.fulgentgenetics.comCEO
Ming Hsieh
Description
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
FLGT Financial Timeline
Browse a chronological timeline of Fulgent Genetics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.46, while revenue estimate is $94.00m.
Earnings released on 1 May 2026
EPS came in at -$0.36 falling short of the estimated -$0.35 by -3.40%, while revenue for the quarter reached $71.14m , beating expectations by +4.47%.
Earnings released on 27 Feb 2026
EPS came in at $0.16 surpassing the estimated $0.03 by +433.33%, while revenue for the quarter reached $83.34m , missing expectations by -2.39%.
Earnings released on 7 Nov 2025
EPS came in at $0.14 surpassing the estimated -$0.24 by +158.33%, while revenue for the quarter reached $84.07m , missing expectations by -1.54%.
Earnings released on 1 Aug 2025
EPS came in at $0.07 surpassing the estimated -$0.23 by +130.43%, while revenue for the quarter reached $81.80m , beating expectations by +0.46%.
Earnings released on 2 May 2025
EPS came in at $0.04 surpassing the estimated -$0.19 by +121.05%, while revenue for the quarter reached $73.46m , missing expectations by -4.57%.
Earnings released on 28 Feb 2025
EPS came in at $0.04 surpassing the estimated -$0.31 by +112.90%, while revenue for the quarter reached $76.21m , beating expectations by +1.09%.
Earnings released on 8 Nov 2024
EPS came in at $0.31 surpassing the estimated -$0.19 by +263.16%, while revenue for the quarter reached $71.74m , missing expectations by -4.84%.
Earnings released on 2 Aug 2024
EPS came in at $0.15 surpassing the estimated -$0.31 by +148.39%, while revenue for the quarter reached $71.03m , beating expectations by +2.83%.
Earnings released on 3 May 2024
EPS came in at -$0.01 surpassing the estimated -$0.33 by +96.97%, while revenue for the quarter reached $64.49m , missing expectations by -1.34%.
Earnings released on 28 Feb 2024
EPS came in at $0.28 surpassing the estimated -$0.30 by +193.33%, while revenue for the quarter reached $70.51m , beating expectations by +6.31%.
Earnings released on 3 Nov 2023
EPS came in at -$0.39 falling short of the estimated -$0.33 by -18.18%, while revenue for the quarter reached $84.69m , beating expectations by +26.13%.
Earnings released on 4 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.33 by +75.76%, while revenue for the quarter reached $67.85m , beating expectations by +8.60%.
Earnings released on 5 May 2023
EPS came in at -$0.22 surpassing the estimated -$0.45 by +51.11%, while revenue for the quarter reached $66.17m , beating expectations by +10.19%.
Earnings released on 28 Feb 2023
EPS came in at -$0.48 surpassing the estimated -$0.56 by +14.29%, while revenue for the quarter reached $67.70m , beating expectations by +13.66%.
Earnings released on 7 Nov 2022
EPS came in at $0.32 surpassing the estimated $0.17 by +88.24%, while revenue for the quarter reached $105.66m , beating expectations by +15.65%.
Earnings released on 4 Aug 2022
EPS came in at $0.78 surpassing the estimated $0.73 by +6.85%, while revenue for the quarter reached $125.34m , beating expectations by +2.15%.
Earnings released on 3 May 2022
EPS came in at $5.08 surpassing the estimated $3.86 by +31.61%, while revenue for the quarter reached $320.27m , beating expectations by +18.25%.
Earnings released on 23 Feb 2022
EPS came in at $3.34 surpassing the estimated $2.61 by +27.97%, while revenue for the quarter reached $251.67m , beating expectations by +31.70%.
Earnings released on 9 Nov 2021
EPS came in at $3.95 surpassing the estimated $3.25 by +21.54%, while revenue for the quarter reached $227.87m , beating expectations by +72.68%.
Earnings released on 9 Aug 2021
EPS came in at $2.47 falling short of the estimated $2.76 by -10.51%, while revenue for the quarter reached $153.62m , meeting expectations.
FLGT Stock Performance
Access detailed FLGT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
